Table 5.
Patient-level survey results.
| Survey 1 | Survey 2 | Survey 3 | |
|---|---|---|---|
| PPI users/all patients | 382/706 | 399/864 | 65/146 |
| prevalence (%) | 54.11 | 46.18 | 44.52 |
| 95% confidence interval | 50.42–57.75 | 42.88–49.51 | 36.70–52.62 |
| Sex ratio (males per females) | 183:199 | 192: 207 | 32:33 |
| Males % | 47.91 | 48.12 | 49.23 |
| Age: mean ± SD | 68.62 ± 15.11 | 69.59 ± 14.21 | 65.69 ± 11.56 |
| min-max | 18–96 | 23–98 | 31–86 |
| Polypharmacy in the PPI user group (number of patients) | unknown | 343 | 59 |
| % | 85.96 | 73.29 | |
| Administered active ingredient: number of patients (%) | |||
| Pantoprazole | 366 (95.81) | 384 (96.24) | 51 (78.46) |
| Lansoprazole | 2 (0.52) | 2 (0.5) | 8 (12.31) |
| Rabeprazole | 2 (0.52) | 3 (0.75) | 5 (7.69) |
| Omeprazole | 3 (0.79) | 2 (0.5) | 0 (0.00) |
| esomeprazole | 9 (2.36) | 8 (2.01) | 1 (1.54) |
| Duration of PPI treatment: number of patients (%) | unknown | ||
| started during hospitalization/after admission | 84 (21.05) | 0 (0.00) | |
| less than 1 year | 99 (24.81) | 3 (4.62) | |
| 1 to 5 years | 125 (31.33) | 48 (73.85) | |
| more than 5 years | 82 (20.55) | 14 (21.54) | |
| missing answer: nine people | |||
| Indication of PPI utilization: number of patients (%) | |||
| Therapy | |||
| GORD | 48 (12.57) | 41 (10.28) | 8 (12.31) |
| Helicobacter eradication | 6 (1.57) | 1 (0.25) | 4 (6.15) |
| Peptic ulcer long-term treatment | 40 (10.47) | 43 (10.78) | 1 (1.54) |
| Prevention | |||
| Stress ulcer prophylaxis | 15 (3.93) | 8 (2.01) | 0 (0.00) |
| Other—”gastro protection” (e.g. ASA, NSAID, polypharmacy) |
273 (71.47) | 296 (74.19) | 52 (80.00) |
| ASA | 47 (12.3) | 118 (29.57) | 27 (41.54) |
| Clopidogrel | no info | 48 (12.03) | 42 (64.62) |
| ASA and Clopidogrel | no info | 40 (10.03) | 18 (27.69) |
| NSAID | 64 (16.75) | 52 (13.03) | 3 (4.62) |
| Anticoagulants* | no info | no info | 4 (6.15) |
| Missing answer | – | 10 (2.51) | – |
*Low molecular weight heparins, vitamin K antagonist, novel anticoagulants.
PPI, proton pump inhibitor; SD, standard deviation; GORD, Gastro-oesophageal reflux disease; ASA, acetyl salicylic acid; NSAID, non steroid anti-inflammatory drugs.